DE112010005017A5 - BETA-CARBOLINE FOR THE TREATMENT OF HEARING DAMAGE AND DIFFICULTY - Google Patents

BETA-CARBOLINE FOR THE TREATMENT OF HEARING DAMAGE AND DIFFICULTY Download PDF

Info

Publication number
DE112010005017A5
DE112010005017A5 DE112010005017T DE112010005017T DE112010005017A5 DE 112010005017 A5 DE112010005017 A5 DE 112010005017A5 DE 112010005017 T DE112010005017 T DE 112010005017T DE 112010005017 T DE112010005017 T DE 112010005017T DE 112010005017 A5 DE112010005017 A5 DE 112010005017A5
Authority
DE
Germany
Prior art keywords
carboline
beta
difficulty
treatment
hearing damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE112010005017T
Other languages
German (de)
Inventor
Hans Rommelspacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AUDIOCURE PHARMA GmbH
Original Assignee
AUDIOCURE PHARMA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AUDIOCURE PHARMA GmbH filed Critical AUDIOCURE PHARMA GmbH
Publication of DE112010005017A5 publication Critical patent/DE112010005017A5/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
DE112010005017T 2009-12-28 2010-12-28 BETA-CARBOLINE FOR THE TREATMENT OF HEARING DAMAGE AND DIFFICULTY Withdrawn DE112010005017A5 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102009060811 2009-12-28
DE102009060811.7 2009-12-28
US28239510P 2010-02-02 2010-02-02
US61/282,395 2010-02-02
PCT/DE2010/001530 WO2011079841A1 (en) 2009-12-28 2010-12-28 Beta-carbolines for use in the treatment of hearing loss and vertigo

Publications (1)

Publication Number Publication Date
DE112010005017A5 true DE112010005017A5 (en) 2012-10-04

Family

ID=44246908

Family Applications (1)

Application Number Title Priority Date Filing Date
DE112010005017T Withdrawn DE112010005017A5 (en) 2009-12-28 2010-12-28 BETA-CARBOLINE FOR THE TREATMENT OF HEARING DAMAGE AND DIFFICULTY

Country Status (17)

Country Link
US (1) US9107914B2 (en)
EP (1) EP2519238B1 (en)
JP (1) JP5627705B2 (en)
KR (1) KR20120098855A (en)
CN (1) CN102844029A (en)
AU (1) AU2010338669A1 (en)
BR (1) BR112012015967B1 (en)
CA (1) CA2785233C (en)
DE (1) DE112010005017A5 (en)
IL (1) IL220661A (en)
IN (1) IN2012DN05066A (en)
MX (1) MX2012007678A (en)
NZ (1) NZ600478A (en)
RU (1) RU2012132429A (en)
SG (1) SG181599A1 (en)
WO (1) WO2011079841A1 (en)
ZA (1) ZA201204476B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2968284T3 (en) * 2013-03-14 2021-06-14 Osteoqc Inc ALKYL-AMIN HARMINE DERIVATIVES TO PROMOTE BONE GROWTH
CA2905842C (en) 2013-03-14 2023-02-21 The Brigham And Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor
EP2853533A1 (en) 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-fluor-9-methyl-ß-carbolin
AU2015311816B2 (en) 2014-09-03 2019-04-04 Massachusetts Institute Of Technology Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
AU2017205194A1 (en) 2016-01-08 2018-07-19 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
EP3321264A1 (en) * 2016-11-14 2018-05-16 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways
WO2018125746A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2020037004A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Pyrrolo - dipyridine compounds
JP2021535091A (en) 2018-08-14 2021-12-16 オステオーク インコーポレイティド Fluoroβ-carboline compound
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
EP3772515A1 (en) * 2019-08-09 2021-02-10 Audiocure Pharma GmbH Stable polymorphic form of 6-fluoro-9-methyl-9h-ss-carboline and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3240514A1 (en) 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen SS-CARBOLINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US20040038970A1 (en) 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
CN1169808C (en) * 1998-06-12 2004-10-06 研究及应用科学协会股份有限公司 'Beta'-carboline compound
US20050143371A1 (en) * 2003-07-23 2005-06-30 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
DE102007009264A1 (en) 2007-02-26 2008-08-28 Ellneuroxx Ltd. New 9-alkyl-beta-carboline compounds are dopamine receptor stimulators useful to treat and/or prevent movement disorder, Alzheimer's disease, Parkinson's disease and Wilson's diseases, and as additives for accelerating cell growth

Also Published As

Publication number Publication date
JP2013515752A (en) 2013-05-09
NZ600478A (en) 2013-10-25
ZA201204476B (en) 2014-01-29
MX2012007678A (en) 2012-09-12
JP5627705B2 (en) 2014-11-19
BR112012015967A2 (en) 2016-04-19
IL220661A (en) 2016-03-31
US20130028958A1 (en) 2013-01-31
BR112012015967B1 (en) 2019-08-27
KR20120098855A (en) 2012-09-05
SG181599A1 (en) 2012-07-30
EP2519238A1 (en) 2012-11-07
IN2012DN05066A (en) 2015-10-09
EP2519238B1 (en) 2014-08-13
WO2011079841A1 (en) 2011-07-07
RU2012132429A (en) 2014-02-10
AU2010338669A1 (en) 2012-06-21
US9107914B2 (en) 2015-08-18
CN102844029A (en) 2012-12-26
IL220661A0 (en) 2012-08-30
CA2785233A1 (en) 2011-06-07
CA2785233C (en) 2018-10-09

Similar Documents

Publication Publication Date Title
DE112010005017A5 (en) BETA-CARBOLINE FOR THE TREATMENT OF HEARING DAMAGE AND DIFFICULTY
IL261768B (en) Devices and methods for the treatment of tissue
HRP20171352T1 (en) Wnt antagonists and methods of treatment
EP2613735A4 (en) Devices and methods for the treatment of vascular defects
DE112011102047A5 (en) Device for wound treatment and wound dressing
BRPI1014864A2 (en) "implantation of spinous processes and associated methods"
GB2498121B (en) Treatment device and method of use
EP2621499A4 (en) Methods for the treatment of allergic diseases
DE112011101025T8 (en) Process for the combined treatment of household waste and wastewater
EP2563268A4 (en) Ultrasonic methods and devices for dental treatment
EP2640395A4 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
FI20135146L (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT
DE102013106683A8 (en) Semiconductor devices and methods of making the same
HK1166305A1 (en) Compositions and methods for the treatment of inflammation
ATE532507T1 (en) NERAMEXANE FOR THE TREATMENT OF SUBACUTE TINNITUS
EP2651439A4 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
BR112012033536A2 (en) shower sterilization system and method of use
IL225793A0 (en) Methods and compositions for the treatment of insulin-associated medical conditions
DE112011105826B8 (en) Semiconductor device and method of making the same
EP2478828A4 (en) Endoscope treatment device and endoscope treatment method
BR112013014915A2 (en) curative composition and treatment methods
EP2575824A4 (en) Methods for the treatment and prevention of inflammatory diseases
FI20095134A (en) Method of operating the holding device and holding device
DE112010001393A5 (en) PLANT EXTRACTS FOR THE TREATMENT OF SKIN DISEASES
DE102010014616A8 (en) Device and method for the treatment of biomass

Legal Events

Date Code Title Description
R120 Application withdrawn or ip right abandoned